{"id":16200,"date":"2026-01-28T11:57:23","date_gmt":"2026-01-28T06:27:23","guid":{"rendered":"https:\/\/www.torusdigital.com\/toruscope\/?p=16200"},"modified":"2026-01-28T12:06:31","modified_gmt":"2026-01-28T06:36:31","slug":"accretion-nutraveda-ipo-opens-key-details-investors-shouldnt-miss","status":"publish","type":"post","link":"https:\/\/www.torusdigital.com\/toruscope\/news\/accretion-nutraveda-ipo-opens-key-details-investors-shouldnt-miss\/","title":{"rendered":"Accretion Nutraveda IPO Opens: Key Details Investors Shouldn\u2019t Miss"},"content":{"rendered":"

[vc_section el_id=”blog-inner-layout”][vc_row overlay_dotted=””][vc_column el_class=”blog_primary”][vc_row_inner][vc_column_inner][vc_column_text css=””]<\/p>\n

India\u2019s IPO market has remained active in early 2026, with several SME offerings gaining attention from investors tracking niche, fast-growing segments. Rising focus on healthcare, wellness, and preventive nutrition has also brought Ayurvedic and nutraceutical manufacturing businesses into the spotlight, especially those catering to both domestic demand and export markets.<\/p>\n

Against this backdrop, Accretion Nutraveda Limited<\/strong> is set to open its IPO on January 28, 2026<\/strong>. Here is a detailed insight into the company, its IPO, and the industry outlook.<\/p>\n

\n

<\/span>About Accretion Nutraveda Ltd.<\/span><\/h2>\n

Incorporated in 2021<\/strong>, Accretion Nutraveda Limited<\/strong> is engaged in the manufacturing of Ayurvedic and nutraceutical products<\/strong> across multiple dosage forms such as tablets, capsules, oral liquids, powders, oils<\/strong>, and external preparations including balms, creams, and gels<\/strong>.<\/p>\n

The company operates as a Contract Development and Manufacturing Organisation (CDMO)<\/strong> and serves both domestic and international markets such as Sri Lanka, Singapore, and the USA<\/strong>. Its product approach blends classical Ayurvedic principles with modern nutraceutical science, focusing on health areas such as liver care, women\u2019s health, bone and joint health, cognitive support, and respiratory wellness<\/strong>.<\/p>\n

<\/span>Business Verticals<\/span><\/h3>\n
    \n
  1. \n

    Domestic Sales and Merchant Exports (Loan License Basis)<\/strong> contributing 96.62%<\/strong> of total revenue in FY 2024 to 25<\/p>\n<\/li>\n

  2. \n

    Direct Exports<\/strong> contributing 38%<\/strong>, with consistent growth<\/p>\n<\/li>\n<\/ol>\n

    The company\u2019s manufacturing facility is located in Gujarat and spans around 10,763 sq. ft.<\/strong>, equipped with modern infrastructure including 13 air handling units, separate processing areas, and quality control systems<\/strong>. The facility holds GMP, WHO GMP, FSSC 22000, ISO 9001:2015, ISO 45001:2018, and Halal certifications<\/strong>, along with an FSSAI license<\/strong>.<\/p>\n

    \n

    <\/span>Accretion Nutraveda IPO Details<\/span><\/h2>\n

    Accretion Nutraveda IPO is a book build issue of \u20b924.77 crores<\/strong>, and the issue is entirely a fresh issue of 0.19 crore shares<\/strong>. The proceeds are proposed to be utilised for automation, new manufacturing setup, working capital needs, and general corporate purposes.<\/p>\n

    \n

    <\/span>Important IPO Timeline<\/span><\/h2>\n
    \n
    \n\n\n\n\n\n\n\n\n\n\n\n
    Event<\/th>\nDate<\/th>\n<\/tr>\n<\/thead>\n
    IPO Open Date<\/td>\nJanuary 28, 2026<\/td>\n<\/tr>\n
    IPO Close Date<\/td>\nJanuary 30, 2026<\/td>\n<\/tr>\n
    Allotment Date (Tentative)<\/td>\nFebruary 2, 2026<\/td>\n<\/tr>\n
    Initiation of Refunds<\/td>\nFebruary 3, 2026<\/td>\n<\/tr>\n
    Credit of Shares to Demat<\/td>\nFebruary 3, 2026<\/td>\n<\/tr>\n
    Listing Date (Tentative)<\/td>\nFebruary 4, 2026<\/td>\n<\/tr>\n
    Anchor Bid Date<\/td>\nJanuary 27, 2026<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<\/div>\n
    \n

    <\/span>Key IPO Details<\/span><\/h2>\n
    \n
    \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
    Particulars<\/th>\nDetails<\/th>\n<\/tr>\n<\/thead>\n
    Face Value<\/td>\n\u20b910 per share<\/td>\n<\/tr>\n
    Issue Price Band<\/td>\n\u20b9122 to \u20b9129 per share<\/td>\n<\/tr>\n
    Lot Size<\/td>\n1,000 Shares<\/td>\n<\/tr>\n
    Total Issue Size<\/td>\n19,20,000 shares (aggregating up to \u20b925 Cr)<\/td>\n<\/tr>\n
    Fresh Issue<\/td>\n19,20,000 shares (aggregating up to \u20b925 Cr)<\/td>\n<\/tr>\n
    Issue Type<\/td>\nBookbuilding IPO<\/td>\n<\/tr>\n
    Listing At<\/td>\nBSE SME<\/td>\n<\/tr>\n
    Shareholding Pre Issue<\/td>\n53,20,000 shares<\/td>\n<\/tr>\n
    Shareholding Post Issue<\/td>\n72,40,000 shares<\/td>\n<\/tr>\n
    Market Cap (Pre IPO)<\/td>\n\u20b993.40 Cr<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<\/div>\n
    \n

    <\/span>Lot Size of Accretion Nutraveda IPO<\/span><\/h2>\n
    \n
    \n\n\n\n\n\n\n\n\n\n
    Application<\/th>\nLots<\/th>\nShares<\/th>\nAmount<\/th>\n<\/tr>\n<\/thead>\n
    Individual investors (Retail) (Min)<\/td>\n2<\/td>\n2,000<\/td>\n\u20b92,58,000<\/td>\n<\/tr>\n
    Individual investors (Retail) (Max)<\/td>\n2<\/td>\n2,000<\/td>\n\u20b92,58,000<\/td>\n<\/tr>\n
    S-HNI (Min)<\/td>\n3<\/td>\n3,000<\/td>\n\u20b93,87,000<\/td>\n<\/tr>\n
    S-HNI (Max)<\/td>\n7<\/td>\n7,000<\/td>\n\u20b99,03,000<\/td>\n<\/tr>\n
    B-HNI (Min)<\/td>\n8<\/td>\n8,000<\/td>\n\u20b910,32,000<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<\/div>\n
    \n

    <\/span>IPO Reservation Details<\/span><\/h2>\n
    \n
    \n\n\n\n\n\n\n\n\n\n\n\n\n\n
    Investor Category<\/th>\nShares Offered<\/th>\n<\/tr>\n<\/thead>\n
    Market Maker Shares Offered<\/td>\n96,000 (5.00%)<\/td>\n<\/tr>\n
    QIB Shares Offered<\/td>\n9,08,000 (47.29%)<\/td>\n<\/tr>\n
    Anchor Investor Shares Offered<\/td>\n5,44,000 (28.33%)<\/td>\n<\/tr>\n
    QIB (Ex Anchor) Shares Offered<\/td>\n3,64,000 (18.96%)<\/td>\n<\/tr>\n
    NII (HNI) Shares Offered<\/td>\n2,76,000 (14.37%)<\/td>\n<\/tr>\n
    bNII (> \u20b910L)<\/td>\n1,84,000 (9.58%)<\/td>\n<\/tr>\n
    sNII (< \u20b910L)<\/td>\n92,000 (4.79%)<\/td>\n<\/tr>\n
    Retail Shares Offered<\/td>\n6,40,000 (33.33%)<\/td>\n<\/tr>\n
    Total Shares Offered<\/td>\n19,20,000 (100.00%)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<\/div>\n
    \n

    <\/span>Competitive Strengths<\/span><\/h2>\n

    \u2022 Experienced promoters and management team
    \u2022 Diverse product portfolio across multiple dosage forms
    \u2022 Commitment to quality standards and certifications
    \u2022 Strong relationships with clients and suppliers
    \u2022 Established business process and management framework<\/p>\n

    \n

    <\/span>Accretion Nutraveda Ltd. Financials<\/span><\/h2>\n

    The Accretion Nutraveda IPO has a pre IPO market capitalisation of \u20b993.40 crore<\/strong>. As of September 30, 2025, the company reported strong profitability metrics, including ROE of 68.54%<\/strong>, ROCE of 49.09%<\/strong>, and a PAT margin of 16.59%<\/strong>.<\/p>\n

    <\/span>Key Company Financials<\/span><\/h3>\n
    \n
    \n\n\n\n\n\n\n\n\n\n\n\n
    Period Ended<\/th>\nSep 30, 2025<\/th>\nMar 31, 2025<\/th>\nMar 31, 2024<\/th>\nMar 31, 2023<\/th>\n<\/tr>\n<\/thead>\n
    Assets (\u20b9 Cr)<\/td>\n16.35<\/td>\n10.86<\/td>\n4.64<\/td>\n4.06<\/td>\n<\/tr>\n
    Total Income (\u20b9 Cr)<\/td>\n14.07<\/td>\n16.06<\/td>\n5.20<\/td>\n3.07<\/td>\n<\/tr>\n
    Profit After Tax (\u20b9 Cr)<\/td>\n2.33<\/td>\n2.61<\/td>\n0.82<\/td>\n0.28<\/td>\n<\/tr>\n
    EBITDA (\u20b9 Cr)<\/td>\n3.29<\/td>\n3.65<\/td>\n1.21<\/td>\n0.59<\/td>\n<\/tr>\n
    Net Worth (\u20b9 Cr)<\/td>\n8.26<\/td>\n5.35<\/td>\n1.08<\/td>\n0.26<\/td>\n<\/tr>\n
    Reserves and Surplus (\u20b9 Cr)<\/td>\n2.95<\/td>\n4.86<\/td>\n0.72<\/td>\n-0.10<\/td>\n<\/tr>\n
    Total Borrowing (\u20b9 Cr)<\/td>\n4.43<\/td>\n3.86<\/td>\n2.17<\/td>\n1.97<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<\/div>\n
    \n

    <\/span>IPO Objects of the Issue<\/span><\/h2>\n
    \n
    \n\n\n\n\n\n\n\n\n
    Issue Object<\/th>\nEstimated Amount (\u20b9 Cr)<\/th>\n<\/tr>\n<\/thead>\n
    Purchase of machineries for automation in existing manufacturing unit<\/td>\n4.22<\/td>\n<\/tr>\n
    Purchase of machineries for new manufacturing setup<\/td>\n8.03<\/td>\n<\/tr>\n
    Funding working capital requirements<\/td>\n5.50<\/td>\n<\/tr>\n
    General corporate purposes<\/td>\nNot specified<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<\/div>\n
    \n

    <\/span>Key Performance Indicators (KPI)<\/span><\/h2>\n
    \n
    \n\n\n\n\n\n\n\n\n\n\n\n
    KPI<\/th>\nSep 30, 2025<\/th>\nMar 31, 2025<\/th>\n<\/tr>\n<\/thead>\n
    ROE<\/td>\n68.54%<\/td>\n81.22%<\/td>\n<\/tr>\n
    ROCE<\/td>\n49.09%<\/td>\n36.98%<\/td>\n<\/tr>\n
    Debt Equity<\/td>\n0.54<\/td>\n0.72<\/td>\n<\/tr>\n
    RoNW<\/td>\n56.50%<\/td>\n48.85%<\/td>\n<\/tr>\n
    PAT Margin<\/td>\n16.59%<\/td>\n16.33%<\/td>\n<\/tr>\n
    EBITDA Margin<\/td>\n23.36%<\/td>\n22.79%<\/td>\n<\/tr>\n
    Price to Book Value<\/td>\n7.71<\/td>\n8.76<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<\/div>\n
    \n

    <\/span>Peer Comparison<\/span><\/h2>\n
    \n
    \n\n\n\n\n\n\n\n\n
    Metric<\/th>\nPre IPO<\/th>\nPost IPO<\/th>\n<\/tr>\n<\/thead>\n
    EPS (\u20b9)<\/td>\n4.91<\/td>\n6.44<\/td>\n<\/tr>\n
    P E (x)<\/td>\n26.27<\/td>\n20.02<\/td>\n<\/tr>\n
    Promoter Holding<\/td>\n100%<\/td>\n73.48%<\/td>\n<\/tr>\n
    Market Cap<\/td>\n\u20b993.40 Cr<\/td>\n\u20b993.40 Cr<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<\/div>\n
    \n

    <\/span>IPO Anchor Investors<\/span><\/h2>\n

    Accretion Nutraveda IPO raised \u20b97.02 crore<\/strong> from anchor investors. The anchor bid date was January 27, 2026<\/strong>.<\/p>\n

    \n
    \n\n\n\n\n\n\n\n\n\n
    Particulars<\/th>\nDetails<\/th>\n<\/tr>\n<\/thead>\n
    Bid Date<\/td>\nJanuary 27, 2026<\/td>\n<\/tr>\n
    Shares Offered<\/td>\n5,44,000<\/td>\n<\/tr>\n
    Anchor Portion<\/td>\n\u20b97.02 Cr<\/td>\n<\/tr>\n
    Lock in end date for 50% shares (30 Days)<\/td>\nMarch 4, 2026<\/td>\n<\/tr>\n
    Lock in end date for remaining shares (90 Days)<\/td>\nMay 3, 2026<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<\/div>\n
    \n

    <\/span>IPO Review<\/span><\/h2>\n

    As per the review by Dilip Davda<\/strong>, the company is engaged in Ayurvedic and nutraceutical manufacturing for healthcare. While the company has shown growth in top and bottom lines, the boosted performance from FY25 onwards raises concerns regarding sustainability in a competitive and fragmented segment. Based on recent financials, the issue is viewed as highly priced, and there may be no strong compulsion to apply.<\/p>\n

    \n

    <\/span>Conclusion<\/span><\/h2>\n

    Accretion Nutraveda Limited offers exposure to the Ayurvedic and nutraceutical CDMO business<\/strong>, backed by a certified manufacturing facility and a diversified product portfolio across multiple dosage forms. Its presence across domestic sales, merchant exports, and direct exports provides a multi-channel revenue profile. However, investors may want to closely evaluate pricing, sustainability of recent growth, and competitive pressures in the healthcare manufacturing segment before making an investment decision.<\/p>\n

    [\/vc_column_text][\/vc_column_inner][vc_column_inner width=”1\/2″][vc_column_text css=””][\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_id=”share_rating”][vc_column_inner width=”1\/2″][vc_column_text css=””]<\/p>\n

    Rate this article<\/h6>\n